Click Therapeutics cut more than a quarter of its workforce shortly after raising Series D funding, according to reporting from Endpoints News. The digital therapeutics startup disclosed a $50 million raise from Boehringer Ingelheim, with the restructuring framed as part of post-financing operational execution. The move underscores the operational squeeze facing digital therapeutics as companies balance scaling clinical evidence and payer readiness against tighter capital discipline. Click’s funding adds to a broader funding cycle for digital health, but the immediate reduction in headcount signals a shift toward efficiency following the Boehringer-backed financing. For investors and partners, the workforce change is a near-term indicator of cost control as the company proceeds with clinical and commercial plans.